209225-00-3

Basic information

• Product Name: 1H-Indene-2-carboxylicacid,2,3-dihydro-4-nitro-(9CI)
• Synonyms: 1H-Indene-2-carboxylicacid,2,3-dihydro-4-nitro-(9CI);4-Nitro-1,3-dihydro-2H-indene-2-carboxylic acid;2,3-Dihydro-4-nitro-1H-indene-2-carboxylic acid;4-Nitro-2-indanecarboxylic acid;1H-Indene-2-carboxylic acid,2,3-dihydro-4-nitro-
• CAS NO: 209225-00-3
• Molecular Formula: C₁₀H₉NO₄
• Molecular Weight: 207.184
• Product Categories: AMINOACID
• Mol File: 209225-00-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 151-153 °C(Solv: ethyl acetate (141-78-6); ligroine (8032-32-4))
• Boiling Point: 411.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.452
• PKA: 4.19±0.20(Predicted)
• CAS DataBase Reference: 1H-Indene-2-carboxylicacid,2,3-dihydro-4-nitro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indene-2-carboxylicacid,2,3-dihydro-4-nitro-(9CI)(209225-00-3)
• EPA Substance Registry System: 1H-Indene-2-carboxylicacid,2,3-dihydro-4-nitro-(9CI)(209225-00-3)

Safety Data

• Hazardous Substances Data: 209225-00-3(Hazardous Substances Data)

Usage

Physical form

Yellow crystalline powder

Solubility

Insoluble in water

Uses

Intermediate in the synthesis of various pharmaceutical compounds and organic chemicals; building block in the synthesis of various heterocyclic compounds

Chemical properties

Possesses nitrate and oxidizing properties due to its nitro group

Commercial/industrial applications

Not widely known for specific applications, but commonly used as a building block in chemical synthesis.

Upstream product

• 25177-85-9 2-indancarboxylic acid 
• 888327-26-2 dimethyl 4-nitro-1,3-dihydro-2H-indene-2,2-dicarboxylate 
• 66126-16-7 1,2-bis(bromomethyl)-3-nitrobenzene 
• 26453-01-0 1H-indene-2-carbonitrile, 2,3-dihydro- 

Downstream Products

• 221234-89-5 4-nitro-N-(4-morpholinophenyl)indan-2-carboxamide 
• 888327-28-4 rac-methyl 4-amino-2,3-dihydro-1H-indene-2-carboxylate 
• 1191414-10-4 methyl 4-({[4-(bromomethyl)phenyl](cyclopentyl)acetyl}amino)-2,3-dihydro-1H-indene-2-carboxylate 
• 1191414-11-5 Methyl 4-{[cyclopentyl(4-{[2-(2-methylpropyl)-5-oxo-5,6-dihydro-4H-1,3,4-oxadiazin-4-yl]-methyl}phenyl)acetyl]amino}-2,3-dihydro-1H-indene-2-carboxylate 
• 888327-27-3 methyl 4-nitro-2,3-dihydro-1H-indene-2-carboxylate 

Relevant articles and documents

Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)

Herein we describe the discovery, mode of action, and preclinical characterization of the soluble guanylate cyclase (sGC) activator runcaciguat. The sGC enzyme, via the formation of cyclic guanosine monophoshphate, is a key regulator of body and tissue homeostasis. sGC activators with their unique mode of action are activating the oxidized and heme-free and therefore NO-unresponsive form of sGC, which is formed under oxidative stress. The first generation of sGC activators like cinaciguat or ataciguat exhibited limitations and were discontinued. We overcame limitations of first-generation sGC activators and identified a new chemical class via high-throughput screening. The investigation of the structure-activity relationship allowed to improve potency and multiple solubility, permeability, metabolism, and drug-drug interactions parameters. This program resulted in the discovery of the oral sGC activator runcaciguat (compound 45, BAY 1101042). Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy.

OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF

The present application relates to novel carboxylic acid derivatives having an oxo-substituted azaheterocyclic partial structure, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS

The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.